226 related articles for article (PubMed ID: 25704135)
1. Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.
Stieglitz E; Ward AF; Gerbing RB; Alonzo TA; Arceci RJ; Liu YL; Emanuel PD; Widemann BC; Cheng JW; Jayaprakash N; Balis FM; Castleberry RP; Bunin NJ; Loh ML; Cooper TM
Pediatr Blood Cancer; 2015 Apr; 62(4):629-36. PubMed ID: 25704135
[TBL] [Abstract][Full Text] [Related]
2. Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.
Yabe M; Ohtsuka Y; Watanabe K; Inagaki J; Yoshida N; Sakashita K; Kakuda H; Yabe H; Kurosawa H; Kudo K; Manabe A;
Int J Hematol; 2015 Feb; 101(2):184-90. PubMed ID: 25504334
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of juvenile myelomonocytic leukemia patients after sequential therapy with cytarabine and 6-mercaptopurine.
Wajid M A; Gupta AK; Das G; Sahoo D; Meena JP; Seth R
Pediatr Hematol Oncol; 2020 Oct; 37(7):573-581. PubMed ID: 32459546
[TBL] [Abstract][Full Text] [Related]
4. Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia.
Patel SA; Coulter DW; Grovas AC; Gordon BG; Harper JL; Warkentin PI; Wisecarver JL; Sanger WG; Coccia PF
J Pediatr Hematol Oncol; 2014 Aug; 36(6):491-4. PubMed ID: 24322499
[TBL] [Abstract][Full Text] [Related]
5. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.
Burnett AK; Russell NH; Culligan D; Cavanagh J; Kell J; Wheatley K; Virchis A; Hills RK; Milligan D;
Br J Haematol; 2012 Aug; 158(4):519-22. PubMed ID: 22639959
[TBL] [Abstract][Full Text] [Related]
6. [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia].
Shao Q; Wang ZD; Zheng XL; Dong L; Han DM; Yan HM; Wang HX; Duan LN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1058-62. PubMed ID: 25130828
[TBL] [Abstract][Full Text] [Related]
7. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
8. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
9. Control of thrombotic thrombocytopenic purpura by sirolimus in a child with juvenile myelomonocytic leukemia and somatic N-RAS mutation.
Maschan M; Bobrynina V; Khachatryan L; Kalinina I; Solopova G; Avdonin P; Nasedkina T; Novichkova G; Maschan A
Pediatr Blood Cancer; 2014 Oct; 61(10):1871-3. PubMed ID: 24590757
[TBL] [Abstract][Full Text] [Related]
10. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
11. A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
Yabe M; Sako M; Yabe H; Osugi Y; Kurosawa H; Nara T; Tokuyama M; Adachi S; Kobayashi C; Yanagimachi M; Ohtsuka Y; Nakazawa Y; Ogawa C; Manabe A; Kojima S; Nakahata T;
Pediatr Transplant; 2008 Dec; 12(8):862-7. PubMed ID: 18397212
[TBL] [Abstract][Full Text] [Related]
12. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
Hecht A; Meyer J; Chehab FF; White KL; Magruder K; Dvorak CC; Loh ML; Stieglitz E
Pediatr Blood Cancer; 2019 Nov; 66(11):e27948. PubMed ID: 31347788
[TBL] [Abstract][Full Text] [Related]
13. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
[TBL] [Abstract][Full Text] [Related]
15. Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
Jakovljević G; Kardum-Skelin I; Rogosić S; Nakić M
Coll Antropol; 2010 Mar; 34(1):251-4. PubMed ID: 20432758
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
Zohren F; Czibere A; Bruns I; Fenk R; Schroeder T; Gräf T; Haas R; Kobbe G
Bone Marrow Transplant; 2009 Dec; 44(12):785-92. PubMed ID: 19430496
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
[TBL] [Abstract][Full Text] [Related]
18. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
19. [Clinical Study on Treatment of Juvenile Myelomonocytic Leukemia with Haploidentical-Hematopoietic Stem Cell Transplantation].
Ding L; Zhu H; Han DM; Wang ZD; Zheng XL; Dong L; Yan HM; Liu J; Zhu L; Xue M; Guo ZK; Wang HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1524-1527. PubMed ID: 29070137
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of juvenile myelomonocytic leukemia.
Liao XY; Qiu KY; Fang JP; Wu RH; Guo SY; Huang K; Zhou DH
Hematology; 2019 Dec; 24(1):577-582. PubMed ID: 31389303
[No Abstract] [Full Text] [Related]
[Next] [New Search]